FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 353:1997-1999 November 10, 2005 Number 19 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Mellinghoff, I. K. PubMed Citation

Glioblastoma multiforme is one of the most aggressive and recalcitrant cancers. A tumor that can be identified radiographically can sometimes be resected, yielding a putatively clean magnetic resonance image postoperatively, but tumor cells are invariably present in areas of the brain that are at a considerable distance from the site of initial diagnosis. The delivery of radiotherapy to a field encompassing the tumor and a margin of 2 to 3 cm increases survival, but not substantially. Systemic treatment may be beneficial, but therapy with nitrosoureas and the methylating agent temozolomide increases survival only slightly. Virtually all patients with glioblastoma multiforme . . . [Full Text of this Article]

Source Information

Dr. Friedman is a professor of neuro-oncology and Dr. Bigner is a professor of cancer research — both at Duke University, Durham, N.C.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.